STM JOURNALS

International Journal of
Biochemistry and Biomolecules Research

Volume 3, Issue 1, 2025
January –June
DOI (Journal): 10.37591/IJBBR

https://journals.stmjournals.com/ijbbr

Review IJBBR

Innovative Approaches in Pediatric Drug Formulation Catering to Specialized Need: Review Article

Mohd. Wasiullah[1], Piyush Yadav[2], Satish Kumar Yadav[3,*], Ratnesh Yadav[4]

Abstract

This detailed article review examines innovations in pediatric drug formulation, highlighting developments that cater to children's specific healthcare needs. It covers pediatric pharmacology and advanced solutions like nanoparticle drug delivery and taste-making techniques, focusing on improving the safety, effectiveness, and acceptability of medications for young patients. The review highlights the benefits for patients, including improved adherence to treatment, fewer side effects, and better overall treatment outcomes. It also addresses regulatory and ethical issues, emphasizing the need for a careful balance between scientific advancements and ethical responsibilities. The conclusion envisions a future with precision medicine and personalized formulations while recognizing. The challenges ahead for pediatric healthcare. It includes novel dosage forms designed for children, like oral liquids, orally disintegrating tablets, and chewable options, as well as advancements in taste-masking technologies to improve medication palatability. The review also emphasizes age-appropriate dosing, personalized medicine strategies, and user-friendly administration devices.

Keywords: Drug formulation, pediatric pharmacology, nanoparticles, patient compliance, regulatory compliance

INTRODUCTION

Pediatrics, the medical field focused on the health of children and adolescents, presents distinct challenges in drug administration. Pediatric patients are not simply smaller adults; their developing bodies and unique physiological characteristics require specialized approaches and solutions. Administering pharmaceuticals to this vulnerable population is complex, differing significantly from adult medicine. This review examines the innovative advancements in pediatric drug formulation and their importance in meeting the specialized needs of young patients [1, 2].

***Author for Correspondence**
Satish Kumar Yadav
E-mail: sik.pharma@gmail.com

[1]Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[2]Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.
[3]Associate Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[4]Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India

Received Date: December 14, 2024
Accepted Date: January 07, 2025
Published Date: February 13, 2025

Citation: Mohd. Wasiullah, Piyush Yadav, Satish Kumar Yadav, Ratnesh Yadav. Innovative Approaches in Pediatric Drug Formulation Catering to Specialized Need: Review Article. International Journal of Biochemistry and Biomolecules Research. 2025; 3(1): 35–43p. DOI: https://doi.org/10.37591/IJBBR.v03i01.198202

SCOPE AND SIGNIFICANCE

Innovation in pediatric drug formulation is a crucial and evolving aspect of healthcare that has gained prominence in recent years. This field's significance is multifaceted, impacting various areas, from drug development to clinical care and, most critically, the well-being of pediatric patients.

Historically, pediatric medicine has grappled with the paradox of using medications primarily developed and tested for adults, often leading to dosages that are empirically reduced. This practice often leads to insufficient dosing, possible side effects, and less-than-optimal treatment results. The challenges of pediatric pharmacology, including differences in physiology,

metabolism, and disease presentation, highlight the necessity for drug formulations specifically designed for this population [3].

Additionally, children often resist taking unpalatable medications, and accurately administering doses can be difficult. Their aversion to bitter or unpleasant-tasting drugs has long contributed to non-compliance, jeopardizing treatment effectiveness. These challenges emphasize the urgent need for tailored pharmaceutical solutions in pediatric healthcare [4].

CHALLENGES AND OPPORTUNITIES

Caring for pediatric patients involves recognizing the specific challenges that come with their unique needs. Unlike adults, children undergo rapid developmental changes during infancy and adolescence, which greatly influence their response to medications. When developing treatment plans for pediatric patients, it is important to consider how children's bodies absorb, distribute, metabolize, and eliminate medications differently than adults.

Moreover, ethical and regulatory concerns arise when conducting clinical trials with children, as they are more vulnerable compared to adults. Balancing the delivery of effective and safe treatments while safeguarding the rights and well-being of pediatric patients requires innovative strategies, not only in drug development but also in the ethical aspects of pediatric research [4].

The pharmaceutical industry, healthcare professionals, regulatory agencies, and researchers are increasingly acknowledging these challenges and the urgent need for innovative solutions. As a result, there has been a noticeable increase in research and development focused on pediatric drug formulations, aiming to improve the safety, efficacy, and overall experience of medication administration for children [5].

PEDIATRIC PHARMACOLOGY

Pediatric pharmacology is a complex and evolving field that focuses on understanding the unique physiological and developmental factors influencing drug absorption, distribution, metabolism, and excretion in pediatric patients. The differences between pediatric and adult pharmacology are significant, requiring a specialized approach to drug formulation and administration. This section delves into the distinctive aspects of pediatric pharmacology, highlighting the need for customized drug formulations for children [6, 7].

Unique Physiological and Developmental Factors

Pediatric patients undergo a series of physiological and developmental changes from infancy to adolescence, which greatly impact how medications are processed and their effects on the body. Understanding these factors is essential to make sure medications are used safely and effectively in children.

- *Absorption:* Children's gastrointestinal physiology differs from adults, with variations in gastric acidity, motility, and transit time. The underdevelopment of the digestive system and the presence of protective mechanisms impact drug absorption in children. Additionally, the use of enteral feeding tubes in younger children can complicate drug delivery [8].
  - *Example:* When administering antibiotics to a young child, such as amoxicillin. In infants or toddlers, the lower gastric acidity and slower gastric emptying time may affect how well the drug is absorbed in the stomach.
- *Distribution:* Differences in body composition, such as varying proportions of water and fat, affect the distribution of drugs. In children, medications may have a smaller volume of distribution and higher concentrations in the bloodstream, which may increase the risk of side effects [9].
  - *Example:* As a result, medications like acetaminophen, which are water-soluble, may distribute more widely to the body. This can lead to higher levels of the drug in the bloodstream than in adults.

- *Metabolism:* enzyme systems responsible for drug metabolism are underdeveloped in infants and young children. As a result, drug clearance tends to be slower, raising the risk of drug accumulation, toxicity, or adverse effects.
  - *Example:* Chloramphenicol is primarily metabolized by the liver through conjugation with glucuronic acid. In neonates, the enzyme systems responsible for this metabolic process are immature, meaning the drug is metabolized more slowly than in adults or older children.
- *Excretion:* Renal function, essential for drug excretion, changes significantly throughout childhood. Drug clearance via the kidneys is age-dependent, influencing the appropriate dosing and frequency of medication in pediatric patients [10].
  - *Example:* An example of pediatric drug excretion is ceftriaxone. In neonates and infants, their immature kidneys clear the drug more slowly, requiring less frequent dosing.
- *Developmental Milestones:* As children grow and develop quickly, their response to medications and the necessary dosages may vary. The age and developmental stage of the child are crucial considerations in pediatric pharmacology.

DIFFERENCES BETWEEN PEDIATRIC AND ADULT PHARMACOLOGY

The key difference between pediatric and adult pharmacology lies in the dynamic nature of pediatric patients. whereas adults have relatively stable physiological profiles, children are continually evolving. this continuous development impacts both the pharmacokinetics (how the body processes medications) and pharmacodynamics (how medications affect the body) of drugs given to pediatric patients. Therefore, assumptions derived from adult studies cannot be directly applied to pediatric populations [11].

In Pediatric Drug Challenges Formulation

The development of safe and effective drug formulations for pediatric patients presents a complex set of obstacles that require thoughtful consideration. Understanding these challenges is crucial for appreciating the intricacies involved in pediatric drug development and the urgent need for innovation. In this section, we examine the key difficulties that pharmaceutical companies, healthcare providers, and researchers encounter when designing drug formulations for children [12].

Palatability and Acceptance

One of the most immediate challenges in pediatric drug formulation is ensuring that medications are palatable and acceptable to young patients. Children are particularly sensitive to taste and texture, and their aversion to bitter or unpleasant-tasting drugs often leads to non-compliance. This issue is even more pronounced for very young children, who may be unable to swallow pills or capsules [13].

Innovations in taste-masking techniques, flavoring agents, and the creation of alternative dosage forms, such as oral liquids and chewable tablets have been vital in addressing this challenge. The goal is to enhance the palatability of medications, thereby encouraging children to take them as prescribed.

Dosage Accuracy

Achieving accurate dosing in pediatric drug formulations is another significant challenge. The varying body weight, surface area, and developmental stages of pediatric patients make a standardized dosing approach often unsuitable. Incorrect dosing – either an overdose or Underdose – can lead to serious consequences, including adverse reactions or ineffective treatment.

In response, pediatric-specific dosage forms have been developed, considering factors like age, weight, and growth stage. Additionally, innovative packaging and dosing devices have been introduced to assist parents and healthcare providers in delivering the correct amount of medication [14].

Safety Concerns

Ensuring the safety of pediatric patients is of utmost importance in drug formulation. Since children's bodies are still developing, they may respond to medications in ways that differ from adults, making

the potential for side effects or toxicity a major concern. Developing formulations that are safe and well-tolerated is a complex challenge. Age-appropriate formulations and dosing guidelines, supported by rigorous safety testing, help alleviate these concerns. Pediatric clinical trials are essential to assess both the safety and efficacy of drugs for children, although conducting such trials raises important ethical issues [15].

Regulatory and Ethical Considerations

The regulatory and ethical considerations surrounding pediatric drug development are particularly complex and require careful navigation.

Organizations like the US Food and Drug Administration (FDA) have set regulations and standards for the testing and approval of medications for pediatric use. These guidelines aim to safeguard the rights and health of pediatric patients while ensuring the quality and safety of the medications.

Conducting clinical trials in children involves significant ethical challenges, as they are considered a vulnerable group. Striking a balance between the need for evidence-based treatment and the ethical obligation to protect children requires innovative approaches and a strong commitment to their welfare [16].

Innovation In Pediatric Drug Formulation: Addressing Specialized Needs

Innovation in pediatric drug formulation has become an essential response to the unique challenges involved in treating young patients. It encompasses a wide range of scientific, technological, and clinical advancements focused on developing drug formulations that are not only safe and effective but also customized to meet the unique needs of pediatric patients. This section explores the latest innovations that are transforming pediatric healthcare.

NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS

One of the most promising advancements in pediatric drug formulation is the use of nanoparticle-based drug delivery systems. nanotechnology enables the encapsulation of drugs in nanoscale carriers, offering several benefits for pediatric patients, these nanoparticles have the potential to increase drug solubility, improve bioavailability, and allow for the controlled release of the medication. For children who have difficulty swallowing pills, nanoparticles can be incorporated into oral liquids or suspensions, making drug administration more manageable [17].

Moreover, nanoparticles can be designed to target specific tissues or cells, minimizing systemic exposure and reducing the likelihood of side effects. This targeted delivery is particularly beneficial for conditions requiring localized treatment, ensuring that only the necessary areas are treated while avoiding unwanted effects in other parts of the body.

Taste-Masking Technologies

Taste-Masking Technologies have transformed the landscape of pediatric drug formulation making medications palatable is essential for ensuring that children follow their prescribed treatment regimens. These technologies function by concealing or covering the taste of drugs that are bitter or have an unpleasant flavor, common techniques include flavoring agents, microencapsulation, and modified-release systems that conceal the taste while preserving the drug's therapeutic effectiveness [18].

The use of taste-masking technologies not only improves patient compliance but also alleviates the emotional stress associated with medication administration for both children and their caregivers.

Pediatric-Specific Dosage Forms

In response to the unique needs of young patients, pharmaceutical companies have developed a variety of pediatric-specific dosage forms.

These Include

Oral liquids, chewable tablets, effervescent formulations, and orally disintegrating tablets. Such formulations are designed with the developmental needs and preferences of children in mind, providing alternatives to traditional pills or capsules.

In addition, these dosage forms often come with calibrated dosing devices, making it easier for parents and healthcare providers to administer the correct dose, thereby reducing the risk of dosing errors.

Development of Age-Appropriate Drug Formulations

The creation of age-appropriate drug formulations has become increasingly important. Rather than adopting a one-size-fits-all model, age-appropriate formulations address the specific needs of different pediatric age groups, from neonates to adolescents. These formulations consider factors, such as swallowing abilities, taste preferences, and metabolic differences, allowing for a more tailored approach to pediatric drug therapy [17].

Innovative Packaging and Administration Devices

Innovative packaging and administration devices have significantly improved the delivery of pediatric medications. Child-resistant yet user-friendly packaging ensures that medications are secure in households with children. Additionally, specialized administration devices, such as syringes or dispensers, are designed for accurate dosing and ease of use, reducing the risk of errors in medication delivery [19].

CLINICAL BENEFITS AND OUTCOMES

The innovations in pediatric drug formulation discussed earlier are not just technological advances; they offer significant clinical benefits and have the potential to substantially improve healthcare outcomes for pediatric patients. This section highlights the tangible advantages of these innovations and their impact on patient well-being and overall healthcare quality.

Enhanced Patient Compliance

One of the primary clinical advantages of innovative pediatric drug formulations is the improvement in patient compliance. Children are more likely to take their medications as prescribed when the medications are palatable, easy to administer, and suited to their developmental stage. Taste-masking technologies, age-appropriate dosage forms, and user-friendly administration devices have collectively made it easier for pediatric patients to adhere to their treatment regimens without resistance. This improved compliance results in more effective treatments and enhanced health outcomes. By reducing the frustration and reluctance often associated with taking medicine, these innovations contribute to a more positive and successful therapeutic experience for young patients [19].

Reduced Adverse Effects

Innovations in pediatric drug formulation also play a pivotal role in minimizing adverse effects. pediatric-specific formulations, calibrated dosing devices, and nanoparticle-based delivery systems enable precise dosing that aligns with the child's age, weight, and developmental stage. This reduces the likelihood of overdosing or underdosing, which could lead to unintended side effects. Furthermore, controlled-release mechanisms in some formulations help maintain stable drug levels in the bloodstream, reducing fluctuations that might trigger adverse effects. All these factors contribute to safer drug administration and a reduced risk of side effects, fostering a more favorable risk-benefit profile for pediatric medications [20].

Enhanced Therapeutic Outcomes

Innovations in pediatric drug formulation ultimately result in improved therapeutic outcomes. When medications are tailored to meet the unique needs and characteristics of pediatric patients, they are more likely to achieve their intended clinical effects. age-appropriate drug formulations ensure that children

receive the correct dose in a form that is easy for them to take, thus increasing the likelihood of treatment success. Furthermore, the accuracy provided by nanoparticle-based drug delivery systems and targeted delivery mechanisms ensures that medications are delivered more efficiently to their intended sites of action. This is particularly beneficial in cases where localized treatment is necessary, reducing the risk of systemic side effects while enhancing the therapeutic response.

Enhanced Overall Patient Experience

The overall patient experience is greatly impacted by innovations in pediatric drug formulation. Medication administration, which can be a source of stress for both pediatric patients and their caregivers, becomes less daunting and more manageable. The introduction of flavored, palatable formulations, as well as age-appropriate dosage forms, transforms the experience of taking medications into a more pleasant and less distressing one. An improved patient experience fosters a positive therapeutic relationship, which can be crucial for pediatric patients who may require long-term or chronic medication management. It reduces anxiety and resistance, making healthcare interactions more collaborative and less adversarial.

Regulatory and Ethical Considerations

While innovations in pediatric drug formulation offer significant promises for improving healthcare for children, they come with a complex set of regulatory and ethical considerations. The safety and well-being of pediatric patients are paramount, and the development and administration of pediatric medications require stringent oversight and ethical diligence. This section explores the regulatory guidelines and ethical considerations that shape the development of pediatric drug formulations [19].

REGULATORY FRAMEWORK FOR PEDIATRIC DRUG DEVELOPMENT

The development and approval of pediatric drug formulations are governed by a stringent regulatory framework, overseen by agencies, such as the U.S. Food and Drug Administration (FDA) in the United States. This framework guarantees the safety and effectiveness of medications for pediatric patients.

Its key components include:

- *Pediatric studies requirement:* Regulatory agencies may mandate pharmaceutical companies to perform pediatric studies for specific drugs.
- These studies assess the safety and effectiveness of medications in pediatric populations. For instance, the FDA has introduced the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA), which require and promote research focused on pediatric needs [20].
- *Age-appropriate formulations:* Regulatory agencies stress the importance of age-appropriate drug formulations. Dosage forms, strengths, and labeling should be tailored to the specific age groups intended for the medication. These requirements ensure that pediatric patients receive drugs suited to their unique needs.

Ethical Considerations

Clinical trials involving pediatric patients necessitate special ethical considerations. Parents or legal guardians must give informed consent, and the child's agreement (assent) is also needed, depending on their age and understanding.

Ethical review boards rigorously evaluate the ethical implications of pediatric clinical trials, balancing the potential benefits with the risks involved.

Ethical Considerations in Pediatric Drug Formulation

The ethical dimension of pediatric drug formulation is intricate and requires careful deliberation.

Some of the main ethical considerations in this field include:

- *Child autonomy:* As children mature and develop the capacity for independent decision-making, their preferences and desires regarding medications must be considered. Achieving a balance between parental authority and a child's evolving autonomy presents ethical challenges.
- *Vulnerable population:* Children are regarded as a vulnerable group in both research and healthcare. They rely on adults to advocate for their well-being, which places an additional ethical responsibility on healthcare providers and researchers to protect their rights and welfare.
- *Equity in access:* Ethical considerations also extend to issues of equity in access to pediatric medications. Ensuring that innovative formulations are available to all pediatric patients, regardless of socioeconomic or demographic background, is a critical ethical concern.
- *Beneficence and non-maleficence:* The ethical principles of beneficence (doing good) and non-maleficence (avoiding harm) are crucial in developing pediatric drug formulations. pharmaceutical companies and healthcare providers must prioritize the safety and well-being of pediatric patients, striving to maximize benefits while minimizing risks [20].

FUTURE DIRECTIONS AND CHALLENGES

The field of pediatric drug formulation is on a path of continuous growth and innovation, as we move forward, it is essential to anticipate the future directions in this field and the challenges that will need to be addressed. This section examines the potential trends and upcoming challenges that will influence the future of pediatric healthcare.

Future Directions

- *Precision medicine:* The emergence of precision medicine has the potential to revolutionize pediatric drug formulation. Tailoring treatments to an individual child's genetic makeup and unique physiological characteristics can improve both safety and efficacy.
- *Personalized drug formulations:* The future may bring about the development of truly personalized drug formulations for pediatric patients. These formulations would be designed based on an individual child's needs, considering factors, such as genetics, metabolism, and health conditions.
- *Non-invasive drug delivery:* Advances in non-invasive drug delivery systems, such as transdermal patches and inhalers, may provide alternative methods for pediatric medication administration, reducing the need for oral formulations that can be challenging for children.
- *Digital health and monitoring:* The use of digital health technologies and monitoring tools is likely to become more prevalent in pediatric drug management. Smart devices could assist parents and healthcare providers in tracking medication adherence and monitoring a child's response to treatment [21].

Challenges Ahead

- *Regulatory complexities:* The regulatory framework for pediatric drug development can be complex, and compliance with evolving regulations will remain a challenge. Pharmaceutical companies will need to navigate the intricate requirements for pediatric studies and age-appropriate formulations.
- *Ethical dilemmas:* Balancing the rights and autonomy of pediatric patients as they mature will continue to be an ethical challenge. It requires a delicate balance to respect their preferences and decision-making abilities while ensuring their safety.
- *Equity in access:* Ensuring equitable access to innovative pediatric drug formulations presents an ongoing challenge. disparities in healthcare access, particularly among underserved populations, must be addressed to ensure that all children can benefit from these advancements.
- *Long-term safety:* It is crucial to monitor the long-term safety of new pediatric drug formulations. some effects, particularly those that may only emerge in adulthood, might not be immediately apparent, making post-marketing surveillance essential.
- *Interdisciplinary collaboration:* Collaboration among pediatricians, pharmacists, pharmacologists, and pharmaceutical scientists is key to advancing the field. Facilitating multidisciplinary teamwork and communication will remain an ongoing challenge [22].

CONCLUSIONS

Innovation in pediatric drug formulation is not just a scientific pursuit but a reflection of our dedication to the health and well-being of the youngest members of society. This review has explored the significant strides made in this field, emphasizing the crucial role these innovations play in meeting the specialized needs of pediatric patients. As we look ahead, the promise of precision medicine, personalized drug formulations, and non-invasive delivery methods offers exciting opportunities to further enhance pediatric healthcare. However, navigating regulatory challenges, addressing ethical concerns, ensuring equitable access, and monitoring long-term safety will continue to require focused effort and vigilance.

In Conclusion, the advancement of pediatric drug formulation goes beyond simply creating improved medications; it is about improving the quality of life and health outcomes for the most vulnerable members of our society. By embracing innovation, adhering to ethical principles, and addressing persistent challenges, we can anticipate a future in which pediatric care is safer, more effective, and more compassionate. This concludes our examination of the evolving and critical field of pediatric drug formulation.

REFERENCES

1. Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: From neonates to adolescents. Adv Drug Deliv Rev. 2006 Apr 20;58(1):4–14.
2. Green DJ, Zineh I, Burckart GJ. Pediatric drug development: outlook for science-based innovation. Clin Pharmacol Therapeut. 2018;103(3):376–378.
3. Smyth RL, Edwards AD. A major new initiative to improve treatment for children. Arch Dis Childhood. 2006;91(3):212–213.
4. Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharma Sci. 2013;102(9):2941–2952.
5. Bartelink IH, Rademaker CM, Schobben AF, Van Den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmaco. 2006;45:1077–1097.
6. Cohen-Wolkowiez M, Moran C, Benjamin Jr DK, Smith PB. Pediatric antifungal agents. Curr Opin Infect Diseases. 2009;22(6):553–558.
7. Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Therapeut. 2014;19(4):262–276.
8. Touw DJ, Graafland O, Cranendonk A, Vermeulen RJ, Van Weissenbruch MM. Clinical pharmacokinetics of phenobarbital in neonates. Euro J Pharma Sci. 2000;12(2):111–116.
9. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37–45.
10. Alcorn J, mcnamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants part I. Clin Pharmaco. 2002;41:959–998.
11. Silverio J, Poole JW. Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics. 1973;51(3):578–580.
12. Bodé S, Dreyer M, Greisen G. Gastric emptying and small intestinal transit time in preterm infants: a scintigraphic method. J Pediatr Gastroenterol Nutr. 2004;39(4):378–382.
13. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundament Clin Pharmacol. 2003;17(3):281–299.
14. Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev. 2006;58(1):4–14.
15. Gosden PE, Bedford KA, Dixon JJ, Speidel BD, Leaf AA, Macgowan AP. Pharmacokinetics of once-a-day netilmicin (4.5 mg/kg) in neonates. J Chemother. 2001;13(3):270–276.
16. Ramezani AM, Shayanfar A, Manzoori JL, Jouyban A. Solubility of some basic drugs in dioxane+ water mixtures at 298.2 K. Latin American J Pharm. 2012;31(8):1176–1181.
17. Millard JW, Alvarez-Nunez FA, Yalkowsky SH. Solubilization by cosolvents: Establishing useful constants for the log–linear model. Int J Pharm. 2002;245(1-2):153–166.

18. Vignesh M, Sivakumar M, Parkavi V, Selvakumar K, Joysa Ruby J. Stabilization of folic acid in liquid dosage form: formulation development, method validation and comparative analysis. Int J Pharm Chem Sci. 2012;1:332–338.
19. Ali AA, Charoo NA, Abdallah DB. Pediatric drug development: formulation considerations. Drug Devel Ind Pharm. 2014;40(10):1283–1299.
20. Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. New Eng J Med. 2006;354(16):1698–1705.
21. Reddy LH, Ghosh B. Fast dissolving drug delivery systems: A review of the literature. Indian J Pharm Sci. 2002;64(4):331–336.
22. Aurora J, Pathak V. Oral disintegrating technologies: Oral disintegrating dosage forms: An overview. Drug Deliv Technol. 2005;5(3):50–54.

